Discover

AMRN
Amarin Corporation plc
16.47
1 x 13.94
1 x 18.88
bid
ask
+
0.53
3.32%
1 @ 04:00 PM
16.47 +0.00 (0.00%)
Ytd17.98%
1y-2.02%
15.81
day range
16.56
12.96
52 week range
20.90
Open15.89Prev Close15.94Low15.81High16.56Mkt Cap345.36M
Vol72.32KAvg Vol78.25KEPS-1.60P/EN/AForward P/E-2.17
Beta1.93Short Ratio12.75Inst. Own17.05%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2950-d Avg14.82200-d Avg15.431yr Est1.00
Earning
DateForEstimateReportedSurprisesurprise %
2025-05-072025-030N/AN/AN/A
2025-03-122024-120N/A-0.06-100.00%
2024-10-302024-090N/AN/AN/A
2024-07-312024-0600.010.06120.00%
2024-05-012024-030N/A0.0375.00%
2024-02-292023-120N/AN/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-06-20Cantor FitzgeraldUpgradeOverweight
2024-06-18Cantor FitzgeraldUpgradeOverweight
2023-10-25JefferiesDowngradeBuyHold
2023-07-20Goldman SachsUpgradeSellSell
2023-07-19Northland Capital MarketsUpgradeMarket PerformMarket Perform
2023-01-06JefferiesUpgradeHoldBuy
Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Insider Holder
DateNameRelationQuantityDescription
2024-08-01BERG AARON D.Chief Executive Officer805.38KPurchase
2024-01-21HOLT PATRICKChief Executive Officer314.43KPurchase
2024-07-30KETCHUM STEVEN BOfficer670.84KConversion of Exercise of derivative security
2023-02-20MIKHAIL KARIMChief Executive Officer283.51KStock Award(Grant)
2024-06-30REILLY THOMAS CHARLESChief Financial Officer94.31KConversion of Exercise of derivative security
2023-01-09WOLD OLSEN PERDirector171.03KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Sarissa Capital Management, LP24.85M11.35M25.15%
2024-09-29Kynam Capital Management, LP12.41M5.67M12.57%
2024-09-29Eversept Partners, LP3.31M1.51M3.35%
2024-09-29Morgan Stanley2.55M1.16M2.58%
2024-09-29SCP Investment, LP2.50M1.14M2.53%
2024-09-29Two Sigma Investments, LP2.38M1.09M2.41%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29SPDR Portfolio Developed World ex-US ETF247.51K113.04K0.25%
2024-09-29Delaware Group Equity Fds IV-Delaware Healthcare Fund190.00K86.77K0.19%
2024-10-30Fidelity NASDAQ Composite Index Fund147.01K67.14K0.15%
2024-09-29SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF135.26K61.77K0.14%
2024-10-30Invesco ETF Tr II-Invesco NASDAQ Future Gen 200 ETF70.68K32.28K0.07%
2024-09-29Blackstone Alternative Multi-Strategy Fund35.53K16.23K0.04%
Split
SplitDate
1 : 202025-04-11
0.1 : 12008-01-18
0.1 : 11998-10-19